The announcement is based on data from a mid-stage trial testing Eli Lilly’s antibody bamlanivimab administered in combination with VIR-7831, an antibody made by Vir and GSK.
The FDA granted emergency use authorization to bamlanivimab Nov. 9 for use in patients with mild to moderate COVID-19.
On March 25, the U.S. government stopped distributing bamlanivimab alone, saying that the increasing emergence of coronavirus variants has made it ineffective as a solo antibody treatment. The U.S. still distributes Eli Lilly’s COVID-19 antibody cocktail, a combination of antibodies bamlanivimab and etesevimab that recieved FDA emergency approval Feb. 9.
GSK and Vir on March 26 filed an FDA emergency use authorization application for VIR-7831 to treat mild to moderate COVID-19 infections.
More articles on pharmacy:
Vaccinations at pharmacies preferred to ones at mass vaccination sites, Biden officials say
J&J to deliver 11M vaccines this week
Moderna ships 100 millionth vaccine dose to US government
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
